RHHBY Stock Recent News

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies. "We are encouraged by the efficacy signals observed across the two.

Basel, 16 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies.

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

STOCKHOLM, June 11, 2025 /PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in SpliceBio. The Spanish biotech company is developing novel therapies for genetic diseases – including ophthalmology, neurology, and other therapeutic areas – by leveraging an innovative intein platform. The platform allows large genes to be split into smaller pieces, delivered separately, and then reassembled to create full-length proteins needed to treat diseases. The USD 135 million Series B financing round will help fund the Phase 1/2 clinical trial of SpliceBio's lead gene therapy candidate, SB-007, which is being developed to treat Stargardt disease. The round was co-led by EQT Life Sciences and Sanofi Ventures, with participation from new investor Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners. Stargardt disease, which leads to progressi

JUPITER, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- In a milestone rarely achieved in the clinical laboratory industry, Access Medical Labs — the largest private diagnostic lab in Florida — has completed a full transition from Siemens to Roche Diagnostics systems in under 6 months.

The global oncology diagnostics market is projected to grow from $77.6 billion in 2024 to $101.5 billion by 2029. Key growth drivers include rising cancer rates, R&D, new product launches, and expansion in emerging markets. This comprehensive report covers market segments, regional insights, and profiles of major players like Roche and Siemens. The global oncology diagnostics market is projected to grow from $77.6 billion in 2024 to $101.5 billion by 2029. Key growth drivers include rising cancer rates, R&D, new product launches, and expansion in emerging markets. This comprehensive report covers market segments, regional insights, and profiles of major players like Roche and Siemens.

The Green Steel Market, valued at USD 7.4 billion in 2024, is expected to reach USD 19.4 billion by 2029, growing at a CAGR of 21.4%. The market is driven by innovative technologies such as electric arc furnaces and hydrogen-based production, aiming to lower carbon emissions in steel manufacturing. Major investments and governmental support bolster this shift toward sustainability. Key regions include North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The rising demand for eco-friendly steel in industries like construction and transportation fuels market growth. The Green Steel Market, valued at USD 7.4 billion in 2024, is expected to reach USD 19.4 billion by 2029, growing at a CAGR of 21.4%. The market is driven by innovative technologies such as electric arc furnaces and hydrogen-based production, aiming to lower carbon emissions in steel manufacturing. Major investments and governmental support bolster this shift toward sustainability. Key regions i

Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting.

David Roche from Quantum Strategy criticizes President Trump's intention to influence the Fed on monetary policy.

Basel, 04 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension for Evrysdi® (risdiplam) to include a new, room-temperature stable tablet for people living with spinal muscular atrophy (SMA). The 5mg tablet (approx. 6.5mm), which can either be swallowed whole or dispersed in water, can be taken with or without food and does not require refrigeration, when stored at room temperature. Administered at home, Evrysdi is the only non-invasive disease modifying treatment available for people living with SMA.